Data Shows Voclosporin Preserves Kidney Function for Three Years
July 19,2023
The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus...
Aurinia Pharmaceuticals
The Lupus Research Alliance Teams Up with the New York Jets for New Jersey Walk with Us to Cure Lupus 20th Anniversary Event
EAST RUTHERFORD, NEW JERSEY. May 6, 2023. An enthusiastic crowd of nearly 1,500 supporters came together today at MetLife...
Lupkynis® (voclosporin) Granted Marketing Authorization in the European Union for Lupus Nephritis
September 21, 2022
Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults...
2022 New Jersey Walk with Us to Cure Lupus Raises Awareness and Funds for Commonly Misdiagnosed Autoimmune Disease
May 14, 2022
EAST RUTHERFORD, NEW JERSEY. May 14, 2022. The Lupus Research Alliance (LRA) brought together thousands of people...
Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis
December 9, 2021
The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia...
Lupus Research Alliance Breaking Through Gala Sets New Record, Raising $7.5 Million for Lupus Research
New York, NY. November 23, 2021 – Last night’s Lupus Research Alliance (LRA) Breaking Through Gala was the most successful...
The Lupus Research Alliance Unites Global Community at Immersive Virtual Walk Experience to Support Lupus Research
NEW YORK, NY. September 30, 2021. The Lupus Research Alliance (LRA) is pleased to invite the global community to...
LRA Congratulates Aurinia on Published Results with FDA-Approved Lupkynis™
May 10, 2021
The highly prestigious medical journal The Lancet published the results of Aurinia’s Phase 3 AURORA 1 study testing...
Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)
First Oral Treatment for Lupus Nephritis;
Second Lupus Treatment to Receive FDA Approval in Past Month
NEW YORK, NY. January...
Results of Two Voclosporin Trials Presented at Key Medical Meeting
October 22, 2020
Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored...
LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA
NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA...
Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis
May 28, 2020
The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application...